Abstract
ObjectiveBraces used to treat (PF) osteoarthritis (OA) may reduce contact stress across the PF joint. We hypothesised that in PF OA, braces would decrease knee pain and shrink PF bone marrow lesions (BMLs).MethodsEligible subjects had painful PF OA. Subjects were randomly allocated to brace or no brace for 6 weeks. Knee MRIs were acquired at baseline and 6 weeks. We measured BMLs on post-contrast fat suppressed sagittal and proton density weighted axial images. The primary symptom outcome was change in pain at 6 weeks during a preselected painful activity, and the primary structural outcome was BML volume change in the PF joint. Analyses used multiple linear regression.ResultsWe randomised 126 subjects aged 40–70 years (mean age 55.5 years; 72 females (57.1%)). Mean nominated visual analogue scale (0–10 cm) pain score at baseline was 6.5 cm. 94 knees (75%) had PF BMLs at baseline. Subjects wore the brace for a mean of 7.4 h/day. 6 subjects withdrew during the trial. After accounting for baseline values, the brace group had lower knee pain than the control group at 6 weeks (difference between groups −1.3 cm, 95% CI −2.0 to −0.7; p<0.001) and reduced PF BML volume (difference −490.6 mm3, 95% CI −929.5 to −51.7; p=0.03) but not tibiofemoral volume (difference −53.9 mm3, 95% CI −625.9 to 518.2; p=0.85).ConclusionsA PF brace reduces BML volume in the targeted compartment of the knee, and relieves knee pain.Trial registration numberUK. ISRCTN50380458.
Subject
General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology
Reference29 articles.
1. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II;Lawrence;Arthritis Rheum,2008
2. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care;Peat;Ann Rheum Dis,2001
3. Increasing prevalence of knee pain and symptomatic knee osteoarthritis: survey and cohort data;Nguyen;Ann Intern Med,2011
4. A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee;Hellio Le Graverand;Ann Rheum Dis,2013
5. Lessons learned from nine clinical trials of disease-modifying osteoarthritis drugs;Brandt;Arthritis Rheum,2005